Major histocompatibility complex presenting tetanus toxoid-derived peptides (MHC-TT)

The Major histocompatibility complex (MHC) presenting tetanus toxoid-derived peptides is a molecular assembly essential for the activation of the adaptive immune response against Clostridium tetani. Tetanus toxoid (TT) is an inactivated toxin that, upon administration via vaccination, is internalized by professional antigen-presenting cells, proteolytically cleaved, and loaded onto MHC Class II molecules, particularly HLA-DR (PubMed: 2525498). These complexes are then displayed on the cell surface where they are recognized by the T-cell receptors (TCRs) of CD4+ T cells. Due to widespread global vaccination, most humans possess a high frequency of memory T cells specific to these MHC-TT complexes (PubMed: 15507524). This pre-existing immunity is frequently leveraged in biotechnology to enhance the efficacy of vaccines and cancer immunotherapies through "bystander help," where the presentation of TT peptides stimulates a localized cytokine environment that supports the activation of other effector cells. Furthermore, the MHC-TT complex is a target for developing novel immunotherapeutic platforms, including bispecific T-cell engagers and TCR-engineered T cells designed to exploit the robust and universal nature of the anti-tetanus immune response (PubMed: 31534003).

Other names

HLA-DR-tetanus toxoid peptide complexMHC-tetanus toxoid epitope complexTetanus toxoid peptide-MHC complexHLA-presented tetanus toxoid peptidespMHC-TT

The complex functions by presenting processed tetanus toxoid epitopes to the T-cell receptors (TCRs) of CD4+ T-helper cells, triggering a memory immune response and cytokine release that can provide bystander help for other antigens.